The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1146
December 23, 2002
View Complete Issue         Table of Contents 2019 
Dutasteride (Avodart) for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dutasteride (Avodart) for Benign Prostatic Hyperplasia
December 23, 2002 (Issue: 1146)
Dutasteride (Avodart - GlaxoSmithKline) is now available in the US for oral treatment of benign prostatic hyperplasia (BPH). It is similar to finasteride (Proscar - Merck), which has been marketed for this indication since 1992 and also, since 1998,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dutasteride (Avodart) for Benign Prostatic Hyperplasia
Article code: 1146b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.